Exodus Point Capital Management, LP Ultragenyx Pharmaceutical Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$43.02 - $53.69 $1.64 Million - $2.04 Million	38,025 New	38,025 $1.78 Million
Q1 2023 May 11, 2023	BUY	$36.99 - $48.71 $2.62 Million - $3.45 Million	70,864 New	70,864 $2.84 Million
Q3 2022 Nov 10, 2022	BUY	$39.96 - $66.14 $1.12 Million - $1.85 Million	27,980 New	27,980 $1.16 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $2.49 Million - $3.28 Million	-31,991 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $2.95 Million - $3.7 Million	31,991 New	31,991 $3.05 Million
Q4 2020 Feb 16, 2021	SELL	$84.4 - $177.39 $250,246 - $525,961	-2,965 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$72.98 - $90.0 $216,385 - $266,850	2,965 New	2,965 $244,000

325

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.07B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.